NO970309D0 - Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri - Google Patents

Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri

Info

Publication number
NO970309D0
NO970309D0 NO970309A NO970309A NO970309D0 NO 970309 D0 NO970309 D0 NO 970309D0 NO 970309 A NO970309 A NO 970309A NO 970309 A NO970309 A NO 970309A NO 970309 D0 NO970309 D0 NO 970309D0
Authority
NO
Norway
Prior art keywords
pct
progesterone antagonist
endometriosis
progestagen
treatment
Prior art date
Application number
NO970309A
Other languages
English (en)
Norwegian (no)
Other versions
NO970309L (no
Inventor
Klaus Stoeckemann
Kristof Chwalisz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO970309L publication Critical patent/NO970309L/no
Publication of NO970309D0 publication Critical patent/NO970309D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO970309A 1994-07-27 1997-01-24 Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri NO970309D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4426601A DE4426601A1 (de) 1994-07-27 1994-07-27 Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
PCT/EP1995/002998 WO1996003130A1 (de) 1994-07-27 1995-07-27 Progesteronantagonist und gestagen zur behandlung der endometriose und leiomyomata uteri

Publications (2)

Publication Number Publication Date
NO970309L NO970309L (no) 1997-01-24
NO970309D0 true NO970309D0 (no) 1997-01-24

Family

ID=6524269

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970309A NO970309D0 (no) 1994-07-27 1997-01-24 Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri

Country Status (22)

Country Link
US (1) US6043234A (zh)
EP (1) EP0772441B1 (zh)
JP (1) JPH10502092A (zh)
KR (1) KR100365879B1 (zh)
CN (1) CN1124848C (zh)
AT (1) ATE213417T1 (zh)
AU (1) AU705618B2 (zh)
CA (1) CA2195425C (zh)
CZ (1) CZ292177B6 (zh)
DE (2) DE4426601A1 (zh)
DK (1) DK0772441T3 (zh)
ES (1) ES2172592T3 (zh)
FI (1) FI970260A0 (zh)
HU (1) HU226453B1 (zh)
IS (1) IS4407A (zh)
MX (1) MX9700309A (zh)
NO (1) NO970309D0 (zh)
NZ (1) NZ291417A (zh)
PL (1) PL318264A1 (zh)
PT (1) PT772441E (zh)
SK (1) SK10497A3 (zh)
WO (1) WO1996003130A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
NZ504351A (en) 1997-11-14 2002-10-25 Akzo Nobel Nv Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
US20080214512A1 (en) * 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
WO2012121767A1 (en) * 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
ES2701400T3 (es) 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
ES2688821T3 (es) 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona
BR112015025706A2 (pt) 2013-04-11 2017-07-18 Bayer Pharma AG forma de dosagem do antagonista do receptor de progesterona
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
FR3078952B1 (fr) * 2018-03-16 2020-03-27 Arianegroup Sas Systeme de mise en orbite de travail pour un satellite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore

Also Published As

Publication number Publication date
CZ292177B6 (cs) 2003-08-13
IS4407A (is) 1997-01-02
NO970309L (no) 1997-01-24
WO1996003130A1 (de) 1996-02-08
PT772441E (pt) 2002-08-30
DE59510069D1 (de) 2002-03-28
EP0772441B1 (de) 2002-02-20
CA2195425C (en) 2008-03-11
CZ20797A3 (en) 1997-05-14
CN1154067A (zh) 1997-07-09
SK10497A3 (en) 1997-08-06
HUT77092A (hu) 1998-03-02
DE4426601A1 (de) 1996-02-01
PL318264A1 (en) 1997-05-26
US6043234A (en) 2000-03-28
FI970260A (fi) 1997-01-22
AU3254395A (en) 1996-02-22
KR970704450A (ko) 1997-09-06
CA2195425A1 (en) 1996-02-08
AU705618B2 (en) 1999-05-27
MX9700309A (es) 1997-05-31
JPH10502092A (ja) 1998-02-24
CN1124848C (zh) 2003-10-22
DK0772441T3 (da) 2002-05-27
FI970260A0 (fi) 1997-01-22
ATE213417T1 (de) 2002-03-15
ES2172592T3 (es) 2002-10-01
HU226453B1 (en) 2008-12-29
NZ291417A (en) 1998-12-23
KR100365879B1 (ko) 2003-03-10
EP0772441A1 (de) 1997-05-14

Similar Documents

Publication Publication Date Title
NO970309D0 (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
DE69518767D1 (de) Ondasetronhaltige oral anzuwendende arzneimittel
IS2034B (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
BR9509019B1 (pt) comprimido isento de solventes orgÂnicos.
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application